Overview

Efficacy and Safety Study of Fluvastatin and Ezetimibe Combined Versus Fluvastatin Alone

Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the effect of the combination treatment on C-reactive protein and inflammatory markers as well as the safety and tolerability in a Spanish population
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Ezetimibe
Fluvastatin